NCT04268628View on ClinicalTrials.gov

A Study of Pharmacodynamic and Genetic Parameters of Abira-DES Study Participants (NCT02217566) - Participants With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Following Unresponsive Treatment With Diethylstilbestrol

CompletedOBSERVATIONAL
Enrollment

42

Participants

Timeline

Start Date

March 19, 2020

Primary Completion Date

November 16, 2020

Study Completion Date

November 16, 2020

Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
OTHER

Serum and plasma samples analysis

This is a non-interventional study and no drug will be given as part of this study. Serum and plasma samples will be collected from the participants with metastatic castration-resistant prostate cancer to evaluate genetic polymorphism and pharmacodynamic parameters.

Trial Locations (1)

01308901

Sociedade Beneficiante de Senhoras - Hospital Sirio Libanes, São Paulo

All Listed Sponsors
lead

Janssen-Cilag Farmaceutica Ltda.

INDUSTRY

NCT04268628 - A Study of Pharmacodynamic and Genetic Parameters of Abira-DES Study Participants (NCT02217566) - Participants With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Following Unresponsive Treatment With Diethylstilbestrol | Biotech Hunter | Biotech Hunter